Sleeve gastrectomy in teens vs young adults

A propensity score-matched cohort study published in Obesity Pillars in August 2026 compared one-year weight loss and metabolic outcomes after laparoscopic sleeve gastrectomy (LSG) in adolescents versus young adults^[1]. Led by Ahmed Taki-Eldin and colleagues across multiple Egyptian centres, the study used matching to control for confounding and directly test whether age group at surgery predicts how well patients do at twelve months.

Why compare adolescents and young adults specifically

The global scale of adolescent obesity makes this comparison clinically urgent. By 2022, more than 160 million children and adolescents aged 5 to 19 were living with obesity worldwide, a figure that has quadrupled since 1990^[2]. Sleeve gastrectomy, which removes roughly 80% of the stomach and reduces the production of ghrelin, a key hunger hormone, is the most performed bariatric procedure globally. It is increasingly offered to adolescents when lifestyle and pharmacological approaches have not produced sufficient improvement in obesity-related health risks^[3].

What makes the adolescent versus young adult comparison meaningful is that these two groups sit at different stages of physical development. Adolescents are still growing, their hormonal environment differs from that of young adults, and the psychological context of major surgery during teenage years raises distinct considerations around long-term adherence and weight maintenance. Whether those differences translate into measurably different surgical outcomes has been an open question.

Study design and what propensity matching adds

Propensity score matching is a statistical method designed to mimic some of the control that randomised trials provide when randomisation is not possible or ethical. By matching each adolescent patient to a young adult with a similar pre-surgery profile (including BMI, comorbidities, and other baseline characteristics), the Taki-Eldin team aimed to isolate the effect of age group itself rather than the baseline differences between the two populations^[1]. The study was published in Obesity Pillars (DOI: 10.1016/j.obpill.2026.100315) as a full-length original paper, with a corresponding PMC record (PMCID PMC13503128), suggesting the full dataset and methodology are available for peer review.

At the time of writing, the paper is behind a paywall and the abstract is not publicly indexed on PubMed in a form we can retrieve. The specific numerical outcomes, the matched sample sizes, and the confidence intervals are therefore not yet available for us to report independently. We will update this article when the full text becomes accessible or the authors present the data at a conference.

What existing evidence suggests to expect

The broader bariatric literature gives some scaffolding for interpreting this kind of comparison. Sleeve gastrectomy in adolescents has generally shown favourable short-term and medium-term outcomes in observational studies, with weight loss and metabolic improvements broadly comparable to those seen in adult populations. The Teen-LABS (Longitudinal Assessment of Bariatric Surgery) programme, a US multicentre study, found that adolescents who underwent bariatric surgery had substantial improvements in weight, type 2 diabetes remission, and hypertension remission at three and five years of follow-up. Separate adult data shows LSG typically produces 25 to 30% excess weight loss at one year in controlled settings^[3].

Young adults, generally defined as those aged 18 to 25 or 18 to 30 depending on the study, share some biological characteristics with older adolescents but have completed the most active period of growth and hormonal flux. They may have a longer duration of obesity before surgery, which is independently associated with more extensive metabolic disruption. Whether that translates into worse or similar metabolic outcomes at one year compared to adolescents is the central question the Taki-Eldin paper addresses.

Where pharmacological treatment fits alongside surgery

Sleeve gastrectomy is not the only option under active investigation for adolescent obesity. GLP-1 receptor agonists are a less invasive alternative that has gained regulatory traction. In the STEP TEENS trial, once-weekly semaglutide 2.4 mg reduced BMI by a mean of 16.1% in 201 adolescents aged 12 to 17 at 68 weeks, compared with a 0.6% increase on placebo^[4]. The FDA approved Wegovy for adolescents aged 12 and older in December 2022 on the basis of those results.

Surgery and pharmacotherapy are not mutually exclusive, and some patients pursue pharmacological treatment before surgery, after surgery for weight regain, or as an alternative when surgical risk is too high. Understanding how surgical outcomes vary by age is therefore relevant not only to surgeons but to the broader clinical team, including those managing semaglutide or other GLP-1 therapies in young patients who are considering or have already undergone bariatric procedures.

What this study does not resolve

One-year data is a useful early marker but does not answer the durability question. Bariatric surgery outcomes in adolescents have shown encouraging short-term results in other cohorts, but longer follow-up studies reveal that some adolescent patients gain weight back in the two to five year window, particularly if structured support and follow-up are not maintained. Metabolic outcomes, including insulin sensitivity, lipid profiles, and blood pressure normalisation, may also diverge from weight outcomes over time. The one-year window captures a period of active loss and initial stabilisation, not the long-term trajectory.

Generalisability is a further consideration. The Taki-Eldin study is conducted in an Egyptian clinical setting. Healthcare system factors, including the surgical experience of the centres, the nutritional counselling available post-operatively, and the baseline health status of the populations, may differ substantially from settings in Europe or North America. Readers and clinicians should interpret the findings in light of their own practice context.

Why the comparison still matters

Whether this paper ultimately finds that adolescents and young adults achieve equivalent or different outcomes at one year, the research question itself is the right one. As bariatric surgery becomes more accepted for adolescents and as GLP-1 therapies like semaglutide expand the range of available treatment options, understanding how age at intervention shapes results helps clinicians and families make better-informed decisions. For the pharmacological side of the obesity treatment picture for younger patients, see our full page on semaglutide.

This article is for educational purposes only. Decisions about bariatric surgery or any obesity treatment for an adolescent or young adult belong with a specialist clinical team that knows the individual case. Consult a healthcare professional before acting on anything you read here.